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Abstract
HIV latency is a major obstacle to curing infection. Current strategies to eradicate HIV aim at increasing transcription of the
latent provirus. In the present study we observed that latently infected CD4+ T cells from HIV-infected individuals failed to
produce viral particles upon ex vivo exposure to SAHA (vorinostat), despite effective inhibition of histone deacetylases. To
identify steps that were not susceptible to the action of SAHA or other latency reverting agents, we used a primary CD4+ T
cell model, joint host and viral RNA sequencing, and a viral-encoded reporter. This model served to investigate the
characteristics of latently infected cells, the dynamics of HIV latency, and the process of reactivation induced by various
stimuli. During latency, we observed persistence of viral transcripts but only limited viral translation. Similarly, the
reactivating agents SAHA and disulfiram successfully increased viral transcription, but failed to effectively enhance viral
translation, mirroring the ex vivo data. This study highlights the importance of post-transcriptional blocks as one mechanism
leading to HIV latency that needs to be relieved in order to purge the viral reservoir.
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Introduction
Successful antiretroviral therapy reduces HIV plasma viremia to
undetectable levels; however, the virus is not eradicated [1].
Current and non-mutually exclusive hypotheses to explain this
phenomenon include (i) the presence of anatomic viral reservoirs
that are inaccessible to drugs, (ii) ongoing viral replication and cell-
to-cell spread, and (iii) the existence of a long-lived cellular
reservoir that is infected but does not produce viral particles and
can be reactivated. With the last hypothesis, it is proposed that
reactivating viral transcription in latently infected cells may help
purging the HIV reservoir and contribute to HIV eradication [2].
Therefore, a better understanding of the mechanisms involved in
viral transcriptional silencing and in the reactivation from latency
is essential. Less attention has been paid to post-transcriptional
blocks which prevent completion of the viral replication cycle, thus
limiting expression of viral proteins, de novo production of viral
particles and cytopathogenesis.
Currently, there are two competing models on how HIV
establishes latency in resting CD4+ T cells [3,4]. The first model
suggests that activated cells are infected by HIV, and that most of
them are productively infected and die within a few days.
However, a minority of cells revert to a resting memory state,
following the natural biology of CD4+ T cells. The second model
proposes that HIV is able to directly infect resting CD4+ T cells,
even if this process is poorly efficient. To study HIV latency
experimentally, cell lines have been used extensively to investigate
the molecular mechanisms underlying impairment of viral gene
expression. Cell lines highlighted viral transcriptional silencing as a
major determinant of HIV latency (reviewed in [5–8]). There is
however increasing interest for work in more representative
primary cell settings. In recent years, multiple systems using
primary cells from various CD4+ T cell subpopulations have been
developed. These systems yield sufficient numbers of cells allowing
investigations that may recapitulate more closely in vivo processes
(reviewed in [4,9].
Primary cell latency models have been used for the screening
and assessment of molecules that promote viral transcription [10].
Multiple compounds [11] reactivate viral transcription from
latently infected cells in vitro, reflecting the various mechanisms
involved in viral transcriptional control, including epigenetic
regulation (such as histone modifications and DNA methylation)
and immune modulation (such as T cell receptor engagement and
protein kinase C signaling) [8,11,12]. The efficiency of these
agents varies according to the HIV latency model used [11,13],
underscoring that the mechanisms leading to repression and
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reactivation of viral transcription may be cell-specific. Some of the
agents are moving forward to clinical trials [1,11,14–16].
We have previously completed a detailed analysis of the cellular
response to HIV infection in a T cell line and derived a model of
cell reprogramming upon viral invasion [17]. Here, we use an
extension of this experimental approach to investigate viral latency
and reactivation in a model of primary CD4+ T cells. We
hypothesized that a comprehensive assessment of the paired
transcriptomes of the host and the virus by RNA sequencing,
coupled to the analysis of viral protein expression, would allow for
addressing the extent of viral transcriptional and post-transcrip-
tional silencing, the structure of the viral transcriptome, and the
nature of the cellular transcriptional program induced by
pharmacological and immunological reactivating compounds.
Our in vitro and ex vivo data reveal defects in viral translation and
particle production that reflect a state of post-transcriptional
cellular latency which may not be reversed by agents merely
enhancing viral transcription.
Results
Viral production from latently infected cells ex vivo
We compared the efficacy of T-cell receptor (TCR) stimulation
and SAHA treatment to stimulate viral particle production ex vivo.
For this, we tested virus release from latently infected cells isolated
from HIV-infected individuals under successful treatment (Table
S1). We isolated resting CD4+ T cells and cultured them for 1, 2,
and 4 days in the presence of IL-2 supplemented with DMSO
(control), SAHA or TCR stimulation. TCR stimulation resulted in
successful viral particle production in 7 of 11 samples, with viral
RNA copies ranging from 42 to 2940 copies/ml of supernatant.
Viral RNA copies in controls (mock-treated cells) were at or below
the limit of detection of the assay for 6 samples, and values ranging
from 27 to 287 copies/ml for 5 samples (Fig. 1). SAHA was
undistinguishable from control, suggesting a failure to stimulate
particle production from latently infected cells ex vivo, confirming
previous studies [18]. We observed effective inhibition of histone
deacetylases confirming that primary cells were exposed to
appropriate concentrations of SAHA (Fig. 1).
Stability of the cellular model of latency
To further investigate the mechanisms underlying SAHA
inefficiency to reactivate latently infected CD4+ T cells ex vivo
and generate viral particles, we used the cellular model described
by the laboratories of Cloyd [19] and Karn [20] that preferentially
produces latently infected CD4+ T cells with a central memory
phenotype. These cells constitute the major cellular reservoir of
HIV in blood [21]. The viral vector, previously used in latency
studies, encodes Tat, Rev, and a destabilized GFP protein with an
estimated half-life of 6 hours [22]. Starting with the transduction
of two million cells from a healthy donor, we sorted a population
of 200,000 successfully infected cells and amplified them to obtain
50 million cells. The infected cell population was then co-cultured
on a feeder layer of the H80 human brain tumor cell line over 10
weeks (Fig. S1). We obtained a population of latently infected cells
carrying a stable number of viral integration events, measured at
1.06 proviruses per cell. This measure of quality control, as well as
the quasi-universal reactivation of the cell population upon T cell
receptor (TCR) stimulation with anti-CD3/anti-CD28 and IL-2
(see below) excluded outgrowth by non-infected cells. The
expression from the env open reading frame of a destabilized
viral-encoded GFP decreased significantly following infection (entry
phase), and reached its nadir upon co-culture on feeder cells (week
0). However, low level GFP expression remained stable at around
3-fold above background (mock uninfected cells) through 10 weeks
of co-culture (latency phase) (Fig. S2). Upon reactivation by TCR
stimulation (reactivation phase), we observed up to 9-fold increase of
GFP expression; with 92% of cells expressing the viral-encoded
GFP, Figure 2. The activation marker IL2Ra (CD25) remained
undetectable during the latency phase. Thus, the model recapit-
ulates the process of latency, although the basal degree of GFP
expression suggests incomplete silencing of HIV.
Incomplete transcriptional silencing of HIV
To understand the extent of viral silencing during latency, we
assessed three parameters of viral transcriptional activity using
RNA sequencing data. First, we estimated the proportion of viral
transcripts among the total number of detected transcripts. From
week 0 (W0) through week 10 (W10), this proportion was stable
with a mean of 1.23% (95%CI; 1.15, 1.32). Second, we evaluated
the distribution of viral reads along the viral vector genome. We
identified a conserved pattern of coverage of the viral vector
genome through the latency phase (Fig. 3A). Third, we assessed
the pattern of viral splicing. All main splice variants were well
represented and in conserved proportions [23] (Fig. 3B, Fig. S3,
Fig. S4). Upon TCR stimulation, there was a proportional shift in
viral splice forms. Indeed, cell activation resulted in a profound
modification of the transcriptome and doubling of the RNA
content of the blasts.
The RNA sequencing approach captures polyadenylated viral
RNA (i.e. fully elongated). On these RNA species we did not
observe major deficits in viral genome coverage, or splicing during
latency. Thus, these viral transcripts could contribute to the
residual viral-encoded GFP expression. However, these analyses
do not discriminate between continuous translation from a stable
pool of viral transcripts from the original infection and de novo
transcription from leakiness of the latency model.
Dynamics of entry, latency, and reactivation
The host RNA profile during the dynamic process of latency
was studied in time-course transcriptome analyses by grouping
host genes according to their transcriptional response to HIV and
to TCR stimulation with anti-CD3/CD28. Whereas the virus only
minimally perturbed the transcriptional state of the cell, TCR
Author Summary
HIV-infected individuals must receive lifelong antiviral
therapy because treatment discontinuation generally
results in rapid viral rebound. The field has identified a
state of latency at the level of transcription of the
integrated provirus as the major mechanism of persis-
tence. A number of drugs are now tested that aim at
inducing viral transcription as a step to purge the reservoir.
The assessment of viral production in cells from HIV-
infected individuals with optimal viral suppression re-
vealed the failure of SAHA/vorinostat to efficiently gener-
ate viral particle production. To further investigate and
characterize the process of latency at the transcriptome
level, and the response to SAHA as well as various
reactivating agents, we use a model of primary CD4+
lymphocytes. The main observation from this study is that
viral transcripts persist during latency, and that the
accumulation of viral transcripts does not result in efficient
viral protein expression upon reactivation with agents
such as SAHA. Our data suggest that post-transcriptional
blocks also contribute to latency, and that additional
strategies need to be explored to efficiently purge the viral
reservoir.
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stimulation resulted in massive cell reprogramming, impacting
66% of all detected genes. Numbers of genes differentially
expressed under the various conditions are detailed in the legend
of Figure 4.
Principal component analysis revealed two transcriptionally
distinct phases: entry (W0–W2) and latency (W4–W10) (Fig. 4B,
Fig. S5). The tight cluster of samples during the 6 weeks of latency
includes both infected and uninfected samples, indicating a stable
process that is only minimally perturbed by the virus. To assess the
differences between infected and uninfected cells, we compared
gene expression in paired samples to pinpoint potential markers of
HIV latency, consistently differentially expressed during the 6
weeks of maintenance of latency (W4–W10): we identified 103
cellular genes as upregulated and 124 as downregulated in HIV-
Figure 1. Viral production from latently infected cells ex vivo. Panel A. HIV RNA copies/ml measured in the supernatant of resting CD4+ T cells
isolated from treated HIV+ individuals (S: cells from single individuals, P: pooled cells from 2-3 individuals) and stimulated ex vivo with DMSO (control,
black), SAHA (blue) or TCR (green) for 1, 2 or 4 days. Panel B. Box plot showing HIV RNA copies/ml measured in the supernatant of resting CD4+ T cells
isolated from treated HIV+ individuals and stimulated ex vivo with DMSO (control, black), SAHA (blue) or TCR (green) for 1, 2 or 4 days. Each circle
represents a different cellular sample. Bars: min to max. Solid line: median. Panel C. Immunoblot of histones (1 mg) extracted from stimulated ex vivo
cells isolated from treated HIV+ individuals. H3K27Ac: anti-histone 3, acetylated Lysine 27; H3K9Ac: anti-histone 3, acetylated Lysine 9; H3: anti-
histone 3 (total).
doi:10.1371/journal.ppat.1004156.g001
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infected samples during this phase. The differentially expressed
genes exhibit moderate enrichment for pathways including
chemokine and cytokine receptors and immune response (Fig.
S6). All differentially expressed genes and analyses can be queried
and downloaded from the open access interactive web resource
http://litchi.labtelenti.org.
The RNA sequence data also allowed for estimating the
diversity of integration sites during the various time points and
upon reactivation. Out of these, we identified 15886 integration
events with reads at a junction between host and HIV transcripts.
Importantly, the data reflects host-virus splicing events that, while
globally identifying the general location of an integration event, do
not allow precise mapping. From this we identified 12868
integration events in the host genome across conditions; ranging
from 3718 at the earliest time point (i.e. 14 days before W0) to
2216 at the latest time point (TCR 24h); 92.5% represented
unique integration sites. Overall, these findings indicate minimal
clonal bias in the model.
In summary, the stability of the cellular transcriptome profile
between weeks 4 and 10 is consistent with maintenance of a resting
state of primary CD4+ T cells and limited contribution from viral
infection. TCR stimulation creates a cellular environment highly
supportive of HIV expression.
Reactivation with pharmacological and immunological
agents
After ten weeks of co-culture on H80, cells were collected and
incubated in the presence of various pharmacological (vorinostat
[SAHA], disulfiram [DSF], 59-azacytidine [AZA]), or immuno-
logical (interleukin 7 [IL-7]) stimuli, as well as TCR stimulation.
We collected RNA for sequencing and cells for FACS analysis at 8
and 24 hours after treatment start. The removal of cells from the
feeder cell layer induced a 2-fold reduction of the proportion of
HIV to all cellular transcripts (from 1.26% to 0.64% at 8 hours),
possibly due to loss of a trophic environment provided by H80
cells (Fig. 5A). In contrast, exposure to SAHA resulted in an
increase in the proportion of viral transcripts to 1.77% at 8 hours
and 2.14% at 24 hours, three times that of DMSO control
(Fig. 5A). The effect of TCR stimulation on the proportion of
HIV transcripts was modest, but cell activation was accompanied
by blast morphology and a 2-fold increase in total cellular RNA at
24 hours. Disulfiram had a transient effect, with an increase in the
proportion of HIV transcripts to 1.63% at 8 hours. IL-7 had a
slower effect with 1.21% at 24 hours. AZA had no detectable
impact on viral transcription. The use of the various agents did not
result in profound changes in viral vector genome coverage or
splicing. However, the use of SAHA was associated with a relative
increase in the proportion of unspliced transcripts (Fig. S3).
Viral transcription induced by activating agents such as SAHA
and disulfiram was not proportionally reflected at the protein level
as expression of the viral-encoded GFP remained low (Fig. 5B).
As previously reported, AZA [24-26] alone, or IL-7 [27] had no
discernible or minimal effects on viral protein expression. This
observation was in contrast to the strong increase in GFP
expression induced by TCR stimulation. The divergent response
was maximal when estimating GFP translation per transcript
(Fig. 5C). Ratios were also assessed by considering the production
of GFP relative to the amount of single-spliced HIV forms, which
have the capability of being translated into GFP. The general
profile of transcription, translation and ratios was not modified in
this analysis.
To understand the differential effect of reactivating agents on
viral transcription, we compared the transcriptional signatures
induced by these agents (Fig. 6, and http://litchi.labtelenti.org).
TCR stimulation showed a very strong effect involving 3664
upregulated and 3220 downregulated genes, with a strong
enrichment signal for upregulation of the cellular machinery
(signal transduction, generic gene expression, protein synthesis,
and metabolism), and upregulation of genes previously proposed
to play a role in HIV biology [28]. In contrast, the various other
agents exerted limited influence on the host transcriptome (Fig.
S7). SAHA induced upregulation of 730 genes and downregula-
tion of 559 genes. Genes involved in immune response and T-cell
activation processes were preferentially downregulated by SAHA.
Disulfiram showed weak effects on cellular gene expression, with
only 132 upregulated genes enriched for HIV cofactors, innate
immunity, and apoptosis, and 57 downregulated genes enriched in
defense response genes. Very little transcriptomic effects were
Figure 2. Dynamics of HIV latency in a primary CD4+ T cell model. Viral-encoded GFP expression (green) and activation marker IL2Ra (CD25)
expression (black) during the steps of entry into latency (week -3 to week 2), maintenance of latency (week 4 to 10), and reactivation upon TCR
stimulation (8, 24, and 72 hours after week 10). Shown are the geometric mean fluorescence of intensity (geoMFI) ratios of HIV-based vector infected
cells and mock non-infected control cells.
doi:10.1371/journal.ppat.1004156.g002
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Figure 3. Features of HIV transcription. Panel A. Distribution of HIV reads along the vector genome. On the top is depicted the viral vector
genome used (NL4-3-D6-drEGFP). Red crosses indicate the genes that are disrupted by stop codon insertion, frameshift or deletion. TSS: transcription
start site; D: splice donor; A: splice acceptor. Reads mapping to the LTR are equally assigned to 59 and 39 ends, explaining the presence of viral reads
upstream the TSS. Panel B. Pattern of splicing for the main viral RNA forms: genomic unspliced full-length viral RNA (US, blue), singly spliced RNAs
without the Gag-Pol major intron (SS, green; spliced in D1 but not in D4), and multiply spliced subgenomic mRNAs (MS, red; spliced in D1 and in D4).
doi:10.1371/journal.ppat.1004156.g003
Dynamics of HIV Latency and Reactivation
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observed in response to the other reactivating compounds (Fig. 6
and http://litchi.labtelenti.org).
To confirm the main findings, we repeated the latency and
reactivation experiment in the same and on an independent
donor. These analyses also included spike-in internal controls for
RNA sequencing and used culture supernatant only from H80
feeder cells (without direct cell-cell contact). The data confirmed
the reproducibility of the model, and the inability of SAHA to
induce viral protein expression in proportion to the increase in
viral transcripts (Fig. S8). Taken together, these results suggest
that, in this model of latency, agents successfully inducing HIV
transcription, such as SAHA and disulfiram, do not lead to
proportional effects on HIV translation. These agents may not
generate a cellular environment that effectively sustains HIV
protein expression. In contrast, cell activation upon TCR
stimulation creates a permissive environment by systematic
activation of the cellular machineries required for viral replication.
These results underscore the need to explore strategies that
facilitate successful completion of the viral cycle in combination
with agents that act primarily on viral transcription.
Discussion
A number of agents have been identified as latency reverting
drugs. SAHA has been extensively studied and brought forward to
clinical trials [14,28,29]. However, data from Blazkova et al. [18],
our data, and recent reports at the time this work was under
consideration [30-32] indicate that SAHA fails to effectively
increase particle production ex vivo. We tested the ability of SAHA
to increase viral production from latently infected CD4+ T cells
from virologically suppressed HIV-infected individuals. While
SAHA effectively inhibited histone deacetylation, it failed to
stimulate particle production as compared to TCR stimulation.
Data from the Siliciano laboratory also indicates that reactivation
induced by SAHA is not sufficient to trigger a cytopathic effect and
cell death [33]. We explored this paradox by using the primary
CD4+ T cell model described by Cloyd [19] and Karn [20].
Use of a primary cell model allowed the detailed analysis of the
dynamic process of HIV latency and persistence. We examined
cellular transcriptional dynamics over 10 weeks and jointly defined
cellular and viral expression patterns using RNA sequencing and
FACS analysis. In this cellular model, latency appears to be a
stable process. However, viral transcripts are continuously present
accompanied by residual expression of viral-encoded GFP. We
reviewed printed material and figures from various primary
models and observed comparable levels of residual GFP or p24
expression that are generally interpreted as background
[10,19,20,34,35] – indeed, the original paper by Tyagi et al.
identified up to 28.77% of cells expressing low levels of GFP
during latency [20]. Upon TCR stimulation, there is near
universal induction of GFP expression, generally validating the
model. The use of SAHA and disulfiram successfully increased
viral transcription; however the reactivated cells failed to produce
proportional amounts of viral protein. Overall, these observations
underscore the importance of the cellular environment to allow
any effect on viral transcription to translate into an efficient
purging strategy [1].
We observed a remarkable stability of the cellular transcrip-
tional profile after 4 weeks of co-culture on H80 feeder cells
despite the presence of HIV transcripts in the cells. Few cellular
genes were differentially expressed between non-infected and
infected cells. These genes may represent biomarkers of HIV
latency, or markers of the original subset of cells that were
successfully transduced. Moreover, the pool of viral transcripts
might persist from the original infection or reflect ongoing
transcription. Cell-associated viral RNA can also be detected in
latently infected resting memory CD4+ T cells in individuals
under effective antiretroviral therapy ([14,36-38], and Hu et al.,
abstract 405, and Fromentin et al., abstract 412, CROI 2014), and
in animal models ([39,40], and Okoye et al., abstract 136LB,
CROI 2014). The short half-life of the viral vector-encoded
destabilized GFP [10] suggests that some residual translation takes
place. Leakiness of the system could be induced by the trophic
environment of the experimental system, including secreted factors
from the feeder cells, or by the small concentration of IL-2 used in
the model. Some level of residual activation has been observed in
other primary cell models [41]. Here, however, we only detected
negligible levels of cellular activation as assessed by expression of
the activation marker IL2Ra (CD25). To better understand the
nature of the persisting viral transcripts, we examined the amount
and distribution of HIV reads along the viral vector genome, and
the pattern of splicing. The proportion of HIV transcripts
remained stable at about 1.26% of all cellular transcripts during
10 weeks, without apparent defects in structure. However, the
RNA sequencing approach captures polyadenylated RNA; there-
fore it would not represent coverage of other species of viral
transcripts, including non-polyadenylated paused viral transcripts
that could be relevant and contribute to the process of latency or
reactivation. The leaky system bears some similarities with that of
infection of cells belonging to the monocyte/macrophage lineage,
which, as discussed by Van Lint et al. [41], may not reach complete
silencing but maintain a low level of viral replication. Therefore,
the model used here may recapitulate both latency and persistence
of viral transcription as already observed in vivo [1]. However, the
experimental system used here has shortcomings. In our hands,
the amount of materials generated is limiting, and the use of a
complete viral clone is too toxic, which led us to use an attenuated
viral vector that only expresses GFP (from env ORF), Rev and Tat.
The use of such a truncated HIV vector may affect the level of
basal HIV transcription and thus the process of latency [42].
Although we are aware of the possibility that, in other types of
vectors, specific transcripts and viral proteins other than GFP
could be selectively expressed (e.g. Gag) [43], the detailed splice
analysis militates against major differences in protein expression
across the viral genome.
We tested three pharmacological agents to induce viral
transcription. SAHA was an efficient inducer, resulting in over
3-fold increase in the proportion of viral transcripts in the cell,
Figure 4. Host transcriptional response in latency and reactivation in a primary CD4+ T cell model. Panel A. Illustrated are 9729 genes
with statistically significant association to at least one of the two experimental conditions, HIV infection and TCR stimulation, as evaluated by 2-way
analysis of variance of 14513 expressed genes (FDR,0.05). Data are presented in three non-exclusive groups: those regulated in concordance with
viral presence (345 genes, top panel), those regulated in concordance with TCR-stimulation 9647 genes, (middle panel), and those showing non-
additive synergetic effects by viral presence and TCR stimulation (59 genes, bottom panel). The bold lines represent the group average, and color
intensities are proportional to statistical significance of the effects within each group. Panel B. Principal component analysis of host whole-
transcriptome data supports a three-step model of entry-latency-reactivation. There is a transcriptionally coherent latency phase between week 4 and
week 10, and a distinct reactivation phase at 8, 24, and 72 hours after TCR stimulation. All data, including differentially expressed genes and
enrichment analysis, are available at http://litchi.labtelenti.org.
doi:10.1371/journal.ppat.1004156.g004
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Figure 5. Response to latency reactivating agents. Panel A. Viral transcription (proportion of HIV transcripts to total cellular transcripts). Panel
B. Viral expression (GFP) profiles after reactivation with the various compounds. Panel C. HIV GFP protein expression corrected by the proportion of
HIV transcript reads in the cell, normalized by DMSO 8 h. The reference lines represent the W0 of latency, and DMSO 8 hour values.
doi:10.1371/journal.ppat.1004156.g005
Dynamics of HIV Latency and Reactivation
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consistent with previous reports [14,16,44,45], reviewed in [5–7].
The effect of disulfiram was short-lived, with a 2.5-fold induction
of viral transcription at 8 hours; also consistent with previous
reports [46]. Despite the observed effects on viral transcription,
these compounds contributed only minimally to viral protein
expression. AZA did not affect viral transcription or translation,
Figure 6. Reactivating agents fail to provide cellular environment necessary for completion of HIV life cycle. Each panel summarizes
over-represented pathways among the differentially expressed genes induced by the indicated treatment. Organized under ten major categories,
each individual circle represents one enriched pathway in Reactome (see methods). The size is proportional to the adjusted p-value (q-value), and the
y-axis corresponds to the average effect of the differentially expressed genes within the reported pathway. Only TCR stimulation using anti-CD3/
CD28 and IL-2 leads to upregulation of numerous cellular pathways, as well as upregulation of reported HIV cofactors and HIV related pathways
(shown in red). AZA is not shown as no enrichment was observed.
doi:10.1371/journal.ppat.1004156.g006
Dynamics of HIV Latency and Reactivation
PLOS Pathogens | www.plospathogens.org 9 May 2014 | Volume 10 | Issue 5 | e1004156
consistent with the mode of action of this drug which needs to be
incorporated into DNA to be active and prevent methylation.
This finding suggests that the cells are not dividing, which again
supports the accuracy of our model. In contrast, in cell lines,
which are dividing, a longer exposure allows observation of
biological effects [24]. In addition, the cellular transcriptional
environment was hardly affected by the various drugs, empha-
sizing that the cells retain a resting state [18,46,47]. Use of IL-7
contributed minimally to enhanced viral transcription or trans-
lation, despite exerting more pronounced effects on cellular
transcription, consistent with recent reports on the use of this
cytokine in vivo [48]. In contrast, the effect on the transcriptome
and the cellular environment created by TCR stimulation
strongly favored translation.
Our data raise the possibility of post-transcriptional block as one
of the mechanisms of HIV latency. This is consistent with studies
from the Fauci laboratory that indicated that resting CD4+ T cells
from aviremic patients did not produce quantifiable cell-free
virions despite the presence of cell-associated HIV-1 RNA [18,49].
Proposed mechanisms underlying post-transcriptional blocks
include splicing defects [43], inhibition of nuclear RNA export
[50], inhibition of expression of viral proteins in a codon-usage-
dependent manner [51], and inhibition of HIV translation by
microRNAs [41,52]. Our current work, and results from Iglesias-
Ussel et al. [53] suggest that latently infected cells may have
multiple biochemical and metabolic blocks that are not completely
released by some of the reactivating agents currently being
evaluated.
Cell line models and primary CD4+ T cell models have
advanced the understanding of basic mechanisms of HIV
transcriptional latency and served to screen for latency
reversing agents. In particular, cell lines highlighted the role
of multiple cis- and trans-acting factors in the regulation of
basal viral transcription [5,7]. Primary cell models provided a
broader view on the complexity of latency and variability in
response to reactivating agents [13,54]. Our work on the
dynamics of latency and reactivation using a primary cell
model underscores the existence of barriers beyond transcrip-
tional silencing – thus helping explain clinical trials and ex vivo
data that identify persistent viral transcription but impaired
viral protein expression and particle production. Overcoming
post-transcriptional blocks may thus require additional inter-
ventions.
Materials and Methods
Viral production from latently infected cells ex vivo
We collected 25 ml of total blood from HIV-infected individuals
participating in the Swiss HIV Cohort Study (http://www.shcs.ch)
with controlled viremia (Table S1). Resting CD4+ T cells were
purified by Ficoll gradient separation followed by negative
selection and magnetic separation using the human CD4+ T Cell
enrichment kit supplemented with anti-HLA-DR, anti-CD25 and
anti-CD69 (Stem Cell Technologies). Cells were resuspended in
Opti/FCS/IL-2, split in three wells (approximately 1 million/ml/
well) containing DMSO, 0.5 mM SAHA, or TCR stimulation as
described below. After 1, 2 or 4 days of incubation, cell
supernatant was collected and assessed for viral presence in a
COBAS AMPLICOR analyzer (Roche), with a limit of detection
of 20 unspliced RNA copies/ml.
Histone immunoblotting
Resting CD4+ T cells from HIV-infected individuals were
isolated and treated for 24 h with DMSO, SAHA or TCR
stimulation as indicated above. Histone extraction was performed
according to Abcam’s protocol. Briefly, cells were washed twice
with ice-cold PBS, resuspended in Triton Extraction Buffer (PBS–
0.5% Triton X100–protease inhibitors–0.02% NaN3) at 10
7 cells/
ml and incubated 109 on ice to allow cell lysis. Cells were
centrifuged at 380 g for 109 at 4uC and washed once with Triton
Extraction Buffer. After centrifugation, the pellet was resuspended
at 46107 cells/ml in 0.2N HCl and incubated over night at 4uC to
allow for histone extraction. Samples were centrifuged at 380 g for
109 at 4uC and the histone-containing supernatant was collected
and protein concentration was measured using Qubit Protein
Assay (Life Technologies) following manufacturer’s protocol.
Histone extracts (1 mg) were separated on an 8–16% SDS-
polyacrylamide gel, transferred to a nitrocellulose membrane and
processed for immunoblotting. Briefly the membranes were
washed with PBS, blocked for 2 h at RT in PBST-milk (PBS/
0.2% Tween-5% non fat dry milk), incubated over night with anti-
histone antibodies (1:1000) at 4uC, washed three times for 109 in
PBST, incubated with swine anti-rabbit-HRP (Dako P-0217,
1:2000) for 2 h at RT, washed again and revealed using Luminata
Crescendo Western HRP substrate (Millipore). Primary antibodies
were rabbit polyclonal from Abcam: anti-H3K27Ac (ab4729),
anti-H3K9Ac (ab10812), anti-H3 (ab1791).
Primary cell model
Primary CD4+ T cells were purified by Ficoll gradient
separation followed by negative selection and magnetic separation
using the human CD4+ T Cell Isolation kit II (Miltenyi Biotec)
(Fig. S1). Cells were activated using CD3/CD28 co-stimulation in
presence of IL-2 (mimicking TCR stimulation) as described
previously [10]. Briefly, anti-CD3 antibodies (10 mg) were plated
in 1 ml PBS per well of a 6-well plate and incubated for 1–2 h at
37uC. Wells were then washed once with 3 ml of PBS and filled
with 106 cells/ml of primary CD4+ T cells supplemented with
1 mg/ml anti-CD28 antibodies in Optimizer CTS T-Cell expan-
sion SFM culture medium containing 5% heat-inactivated fetal
calf serum (FCS) and 100 U/ml human recombinant IL-2 (Opti/
FCS/IL-2 culture medium). Three days post-stimulation, cells
were collected, washed and resuspended at 106 cells/ml in Opti/
FCS/IL-2 for infection with an HIV-based vector (NL4-3-D6-
drEGFP/CXCR4; a kind gift from R.F. Siliciano). This HIV
vector uses a CXCR4 tropic HIV envelope for entry, contains
functional tat and rev genes, as well as a gfp reporter gene
containing a PEST sequence (yielding a protein half time of
,6 hours); this vector contains mutations (stop codons, frameshift
or deletion) in gag, vif, vpr, vpu, env and nef and is thus less cytotoxic
for the infected cell, thereby promoting latency in a higher
proportion of infected cells [10]. HIV particles were produced by
transfection of HEK293T cells as previously described [22].
Infection was carried out by spinoculation for 3 hours at 25uC and
at 1500 g using 50 mg p24 equivalent HIV vector/106 cells in
presence of 5 mg/ml polybrene. After spinoculation, cells were
washed and resuspended at 106 cells/ml in Opti/FCS/IL-2.
Forty-eight hours post-infection, cells were resuspended in PBS/
FCS (to eliminate the interference of phenol red) and sorted by
FACS according to GFP expression, yielding a typical purity of .
98%. FACS sorting was performed with a Mo-Flo Astrios
instrument. Upon sorting, successfully infected GFP+ cells were
further processed to investigate HIV latency.
Establishment and maintenance of HIV latency was mostly
carried out as previously described [19,20] (Fig. S1). Infected
GFP+ cells stimulated using anti-CD3 and anti-CD8 antibodies in
presence of IL-2 as described above were expanded in Opti/FCS/
IL-2 for ,3 weeks, typically allowing ,2 log of cell multiplication.
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At this time (week 0), cells were washed, resuspended in R-10/IL-2
(RPMI-1640 culture medium supplemented with 10% heat-
inactivated FCS and 40 U/ml IL-2) and added to an adherent
H80 feeder cell layer. The H80 human brain tumor cell line,
known to promote ex vivo survival of primary CD4+ T cells, were
prepared by plating 106 cells/25 cm2 flask (T25) or 36106 cells/
75 cm2 flask (T75) the day before starting co-culture with primary
CD4+ T cells. CD4+ T cells were resuspended in R-10/IL-2 and
added on top of the feeder cell layer, in 16 ml R-10/IL-2 in T75 if
30-1006106 primary CD4+ T cells or in 5 ml R-10/IL-2 if .
306106 cells. Culture medium was changed three times a week by
renewing half of it. Every two weeks, CD4+ T cells were collected
and transferred onto a new feeder cell layer flask. During this
transfer, cell samples were collected for analyses (see below). The
co-culture of primary CD4+ T cells with H80 feeder cells was
carried over a period of 10 weeks to allow CD4+ T cells to revert
to a resting phenotype and to ensure entry into and maintenance
of latency. Collected samples were used for: (i) assessing the
expression of virally-encoded GFP and of the marker of activation
IL2Ra (CD25) by FACS analysis, and (ii) assessing dynamic
changes of the cellular and viral transcriptomes using mRNA-Seq.
This analysis allowed for (a) following the cellular dynamic process
from activated to resting state at the transcriptional level in non-
infected as well as infected cells, (b) highlighting genes differentially
expressed in HIV-infected cells as compared to mock cells, and (c)
measuring concomitant viral transcriptional activity in resting
CD4+ T cells. The latency process was also repeated using H80
supernatant as alternative to cell-to-cell contact conditions.
Reactivation
We included pharmacological and immunological agents that
affect HIV transcriptional activity by different mechanisms of
action and that are currently under clinical consideration.
Specifically, we used a histone deacetylase inhibitor (vorinostat
or SAHA, 0.5 mM), a DNA methylation inhibitor (59-azacytidine,
1 mM), an alcohol dehydrogenase inhibitor (disulfiram, 0.5 mM).
All drugs were suspended in dimethyl sulfoxyde (DMSO), thus
DMSO was used as a negative control (of note, final DMSO
concentration was 0.0033% corresponding to 1:30,000 dilution).
We also used immunological stimulation by interleukin-7 cytokine
(100 ng/ml), and a full TCR stimulation using anti-CD3/anti-
CD28 antibodies in presence of interleukin-2. At 8 h and 24 h
after treatment, cells were analyzed for GFP expression by FACS
and for transcriptome composition as described below.
RNA sequencing
Cell samples were stored in RNALater at the time of collection.
Once all samples, from week 0 to week 10, were collected, total
RNA extraction was performed using Illustra RNAspin mini
isolation kit (GE Healthcare) and further processed for mRNA-Seq
library preparation (TruSeq RNA sample prep kit, Illumina – that
starts with capture of polyA-containing transcripts), followed by
cluster generation (TruSeq single-end cluster generation kit,
Illumina) and high-throughput sequencing on Illumina HiSeq2000
at the Genomics Technology Facility, University of Lausanne.
Addition of RNA spike-ins were also added according to
manufacturer’s instructions (ERCC Exfold RNA Spike-in Mixes,
Life Technologies and Loven et al. [55]). We obtained about 100
mio single end reads of 100 nucleotides for each sample. The
sequencing reads were cleaned before alignment in order to
improve the accuracy of downstream analyses. The cleaning steps
included the removal of (i) Illumina’s adapter (if present at the 3’
end of the read) with cutadapt v0.9.5 [56], (ii) low quality (PHRED
score,6) nucleotides at the 39 or 59 end of the reads, (iii) reads
with mean PHRED score lower than 20 and (iv) polyA tails with
prinseq v0.17 [57]. Only reads of 30 nucleotides or longer after
trimming were kept for further analyses. The cleaned reads were
aligned to the reference genome with TopHat v2.0.6 [58] using
the ensembl gene GRCh37 release 68 annotation file. The
reference genome was built by concatenating the human genome
(hg19) and the HIV vector sequence. The number of reads per
gene was extracted with a modified version of HTSeq-count v0.5.3
(http://www-huber.embl.de/users/anders/HTSeq/doc/count.
html) using the same annotation file and considering the whole
HIV vector as a single gene. The modifications allowed multiply
aligned reads to be weighted accordingly. Ambiguous reads
were randomly attributed to one of the genomic regions they
aligned to. To identify integration sites we used Tophat fusion
with bowtie1 and default parameters.
Variance stabilization
Two-way analysis of variance and principle component analysis
(PCA) were used for quantitative assessment of the transcriptome
data presented in Fig. 4. In order to fulfill the underlying
assumptions of these models, we conservatively discarded lowly
expressed genes to minimize heteroscedasticity due to shot noise.
Retaining genes expressing at least 100 reads in more than half of
the samples yielded 14,513 genes. The resulting dataset was
smoothed by adding pseudocounts (10 extra reads per gene), and
log-transformed for variance stabilization.
Differential expression tests
Differential expression tests were performed assuming negative-
binomially distributed read counts using the Bioconductor package
DESeq [29]. Paired-sample differential expression tests were
performed using generalized linear models and dispersions were
estimated using the Cox-Reid-adjusted maximum likelihood
estimator. Lowly expressed genes were discarded after estimating
dispersion. All p-values were corrected using a false discovery rate
of 5% (Benjamini-Hochberg procedure [59]).
Pathway enrichment analysis and visualization
Enrichment analyses were performed using Fisher’s exact test to
detect overrepresentations of functional classes, regulatory motifs
(among miRNA and transcription factor targets), physical
locations on chromosomes, and HIV-related pathways, proteins
and co-factors as described previously [17]. HIV co-factors include
genes in HIV related pathways from the Reactome pathways
database Ver.40, genes identified in previous siRNA studies [60–
63], and genes encoding protein interaction partners for each viral
protein ([28] and http://mint.bio.uniroma2.it/virusmint). All p-
values were corrected using a false discovery rate of 5%.
For visualization in Fig. 6, we only considered enrichment hits
from Reactome pathways and HIV co-factors databases. The
major pathway categories were chosen from maximal pathways,
(Pi), among all the reported unique enrichment hits pooled over all
reactivating agents. In order to choose the most representative
pathway categories, we defined the asymmetric coverage score of
the ith pathway, Pi, over the j
th pathway, Pj, as mi,j=|Pi > Pj|/|Pj|
and the total coverage of the ith pathway as Si=gj mi,j. The set of
representative categories was built by those with the highest total
coverage score Si. We used the nine top categories plus a pseudo-
pathway called ‘‘miscellaneous’’ for the visualization. Each
pathway was assigned to the major category that holds the highest
coverage score over it. Subsequently, the pathways that are not
covered more than 95% in any of the chosen major categories are
assigned to the miscellaneous category.
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Data and materials availability
All data, including differentially expressed genes and enrich-
ment analyses, are freely available in interactive mode or for
downloading at http://litchi.labtelenti.org.
Bioinformatics of viral transcriptome
Two splice junction aligners were used to identify HIV splicing
events: Tophat v2.0.6 and STAR v2.3.0 [64]. All acceptor-donor
pairs were retrieved and their proportion calculated. Both splice
junction aligners gave similar and consistent results. The HIV
transcriptome profile was assessed using the Python package
HTSeq (http://www-huber.embl.de/users/anders/HTSeq/doc/
overview.html). Coverage was normalized by the sample size
factor estimated using DESeq. To calculate the percentage of
HIV transcripts among all transcripts, we compared the
gene length normalized counts using the length of the longest
annotated transcript (isoforms with intron retention were not
considered).
The main viral RNA forms were estimated as follows. The
number of reads overlapping the D1 junction corresponds to
unspliced reads (US, non-spliced in D1). The number of reads
aligning to the left of D1 and broken at D1 (up to a different HIV
position) corresponds to reads spliced in D1 and thus belongs to
singly spliced or multiply spliced HIV RNA (MS+SS). The
number of reads overlapping the D4 junction corresponds to singly
spliced or unspliced HIV transcripts (US+SS). The number of
reads aligning to the left of D4 but broken at D4 (up to different
HIV position) corresponds to reads spliced in D4 and thus belong
to multiply spliced transcripts (MS). Finally, the total proportion of
reads (100%) is US+MS+SS, and SS can be obtained as
SS= 100%–US–MS.
Supporting Information
Figure S1 Experimental design. Cellular model.
(PDF)
Figure S2 FACS analysis of HIV-encoded GFP expres-
sion of representative cell samples. Panel A. CD4+ T cells
were analyzed by FACS to assess the geometric mean fluorescence
intensity of GFP expression (FL1-H channel). The histogram plot
shows uniform populations (single peaks) for uninfected controls
(W10+24 h DMSO, dotted grey line), latently infected cells (W10,
red solid line), latently infected cells upon 24h reactivation with
DMSO (black solid line), SAHA (blue solid line) or TCR
stimulation (green solid line). Data revealed a shift in intensity of
TCR-stimulated cells but not SAHA-treated cells as compared to
the corresponding DMSO control. Panel B. Dot plots of FSC/
SSC or FL1/FL2 of CD4+ T cells, either mock or HIV-infected,
at week 10 post co-culture on H80 (W10) and 24 h post TCR
stimulation (TCR). FSC/SSC dot plots shows differences in cell
size and complexity between W10 and TCR, likely representative
of resting CD4+ T cells and activated CD4+ T cells respectively.
FL1/FL2 dot plots shows highly expressing GFP cells in R7 region
upon TCR stimulation.
(PDF)
Figure S3 Features of HIV transcription under several
reactivation agents. Panel A. Distribution of HIV reads along
the vector genome; each panel compares one agent against
DMSO as control. On the top is depicted the viral vector genome
used. TSS: transcription start site; D: splice donor; A: splice
acceptor. Reads mapping to the LTR are equally assigned to 59
and 39 ends. Panel B. Pattern of splicing for the main viral RNA
forms: genomic unspliced full-length viral RNA (US, blue), singly
spliced RNAs without the Gag-Pol major intron (SS, green; spliced
in D1 but not in D4), and multiply spliced subgenomic mRNAs
(MS, red; spliced in D1 and in D4).
(PDF)
Figure S4 Features of HIV transcription under several
reactivation agents. Detailed assessment of donor-acceptor
splice junction usage and graphical representation. D: splice
donor; A: splice acceptor.
(PDF)
Figure S5 Principal component analysis of latency and
TCR stimulation compared to H80 feeder cells. The
transcriptome of H80 feeder cells (two replicates) is distinct. There
is no evidence for contamination of primary CD4+ T cells during
the process of latency. Upon TCR stimulation, the CD4+ T cells
are removed from the H80 feeder cells.
(PDF)
Figure S6 Pathway enrichments for the differentially
expressed genes during HIV latency. Each panel summa-
rizes over-represented pathways among the differentially expressed
genes induced by viral presence. Organized under nine major
categories, each individual circle represents one enriched pathway
in Reactome (see methods). The size is proportional to the
adjusted p-value (q-value), and the y-axis corresponds to the
average effect of the differentially expressed genes within the
reported pathway.
(PDF)
Figure S7 Principal component analysis of modifica-
tions in the transcriptome upon exposure to the various
reactivating agents. The transcriptome of CD4+ T cells
exposed to the various reactivating agents cluster with that of
mock and of latently infected cells (W4 to W10), suggesting a
minimal impact of those compounds on the cell. Panel A shows the
transcriptome data in the context of latency phase and full cell
activation by TCR stimulation. Panel B shows a PCA analysis on
the large cluster of cells exposed to reactivating agents. The PCA
of the cluster reveals small compound- and HIV-specific
transcriptome differences compared to W10 infected and unin-
fected CD4+ T cells.
(PDF)
Figure S8 Validation and reproducibility of the model.
Panel A. Viral transcription (viral-encoded GFP transcripts
normalized by internal control and by baseline DMSO values)
upon SAHA or TCR stimulation on two donors. Panel B. Viral
expression (GFP MFI) profile after reactivation with SAHA or
TCR on two donors. Panel C. Principal component analysis of
modifications in the transcriptome upon exposure to the various
reactivating agents. An additional experiment was performed to
include cellular samples prior co-culture with H80 cell supernatant
(mD14, mD12 and mD9 corresponding to cells collected 14, 12
and 9 days before W0 respectively). This additional set of CD4+ T
cell transcriptomes recapitulates the entry, latency and TCR
reactivation that were already observed. Exposure to H80 did not
require cell-to-cell contact as the experiment used only filtered
H80 cell culture supernatant. These additional cellular samples
also included RNA spike-in controls (spike) to control for RNA
content differences; normalization data using library size or RNA
spike-in were similar.
(PDF)
Table S1 Characteristics of HIV-infected individuals
included in the ex vivo activation study.
(PDF)
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